MN/CA IX and cancer prognosis

US7993852B2 · kind B2 · utility

Assignee

• Institute of Zoology, Slovak Academy of Sciences · SK

Inventors

• Matthias Ebert · Dettelbach, DE
• Christoph Röcken · Magdeburg, DE
• Silvia Pastorekova · Bratislava, SK
• Jan Zavada · Praha, CZ
• Jaromir Pastorek · Bratislava, SK

Key dates

• Filing date: May 5, 2010
• Grant date: Aug 9, 2011
• Expiry date: May 5, 2030

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/82
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic/neoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic/neoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids.